When Cathie Wood speaks, people listen. The chief executive of Ark Investment Management has had a far-from-perfect record when it comes to her investment choices -- not to mention not exactly flattering feedback from CNBC's Jim Cramer. When asked what stock Wood would choose she won a million dollar lottery and was forced to choose a stock for ten years, Wood's pick was just as disruptive as her reputation.
On any list of biotech plays that might multiply in value in a relatively short period, Cassava Sciences (NASDAQ: SAVA) is likely to be near the top of the list. It's exploring whether its drug called simufilam is safe and effective to treat early-stage Alzheimer's disease, though its clinical trials have (so far) shed little light on the issue. The biggest reason to sell Cassava stock: After an open-label phase 2 clinical trial of simufilam, the market reacted quite negatively to the release of new data that management spun as being positive.
Shares of Coinbase (NASDAQ: COIN) have gotten crushed since hitting public markets, but the business is in better shape than you might think. There's billions of dollars in cash on the balance sheet, and there are growing revenue sources from USDC and Ethereum (CRYPTO: ETH) staking.
For the third day in a row, Tesla (NASDAQ: TSLA) stock is riding higher -- up 4.3% as of 10:10 a.m. ET. The Federal Reserve's decision to raise interest rates only 25 basis points yesterday is probably part of the reason for that -- indeed, growth stocks in general seem happy to run today, with the entire Nasdaq up nearly 2%. Tesla's plan to cut the prices of its electric cars, you see -- not just in the U.S., but in China as well -- is having its intended effect of stoking consumer demand.
The Nasdaq Composite dipped into a bear market last year, and the tech-heavy index is still 28% off its high. Investors often overreact to good and bad news, so stocks tend to rise too high during bull markets and fall too far during bear markets. Warren Buffett hinted at that quirk of human nature when he said, "Be fearful when others are greedy, and be greedy when others are fearful."
A short squeeze occurs when short-sellers rush to cover their positions on a stock. The sudden rush of buying can quickly push a stock price higher. After a tough market year in 2022, some stocks have built up large short-seller followings, potentially priming the pump for a new wave of short squeezes.
Despite a dismal performance in 2022, shares of all-digital bank SoFi Technologies (NASDAQ: SOFI) climbed 50.3% in January. There are lots of reasons for the run-up, not least of which were a better-than-expected performance during the fourth quarter of 2022 and an improved outlook. Will the big gains SoFi made in January fizzle out in February, or is the stock at the beginning of a much longer bull run?
Thursday is a big day for tech earnings as Alphabet, Amazon and Apple all are set to report their quarterly results.
Change doesn't have to be bad.
Top health insurance company Humana (NYSE: HUM) wasn't necessarily tops with investors on Wednesday. After reporting its latest set of quarterly figures, the company's share price bumped slightly higher, by 0.3%, which wasn't high enough to beat the S&P 500 index's more than 1% increase. It's not that Humana's results for the fourth quarter 2022 were bad or uninspiring; it's just that they didn't excel.
Brent Thill, Jefferies Equity Research Analyst, analyzes Meta's stock pop after earnings. You can see the full interview here. Key video highlights 00:25 On how Instagram has improved 00:40 On better ad targeting 00:55 On other social platforms 01:30 On the stock move
Dividend investors should consider loading up on these stocks as this could be a good year for both of their businesses.
(Bloomberg) -- Most Read from BloombergMerck Covid Drug Linked to New Virus Mutations, Study SaysAdani Crisis Deepens as Stock Rout Hits $108 BillionPorsche Blunder Puts $148,000 Sportscar on Sale for Just $18,000Plenty of Americans Are Drinking Bleach, Still for Sale on AmazonHong Kong to Give Away 500,000 Air Tickets to Revive TourismOPEC’s crude output edged lower last month as the group pressed on with an accord to keep global markets in balance.The Organization of Petroleum Exporting Countr
These high-octane income stocks, with yields ranging from 4.3% to 15.4%, have been bought hand over fist by billionaire investors.
Next-generation assisted-driving tech company MicroVision (NASDAQ: MVIS) had a macro Wednesday as far as its stock performance was concerned. The deal will allow MicroVision to integrate the privately held, Germany-based company's perception software features into its MicroVision ASIC assisted-driving system. At the time, the buyer wrote in a press release that "Together, MicroVision's MAVIN lidar hardware and Ibeo's mature software will position MicroVision as a leading hardware and perception software partner to [original equipment makers]."
Did you know that if a company were to increase its dividends by 5% per year, it would take 14 years for its payouts to double? A couple of stocks with the most aggressive dividend growth records you can invest in today are UnitedHealth Group (NYSE: UNH) and Broadcom (NASDAQ: AVGO). Health insurance giant UnitedHealth Group may not strike income investors as an ideal dividend stock to buy, as it yields just under 1.4%, which is below the S&P 500's current average yield of 1.7%.
Tech editor Dan Howley takes a closer look at Meta's latest earnings beat alongside updates to its share buyback program.
In the latest trading session, Deere (DE) closed at $426.99, marking a +0.98% move from the previous day.
Affirm Holdings (AFRM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
January has now been and gone and turned out to be a nice gift for investors. Battered by 2022’s bear, the tech-heavy Nasdaq, in particular, put in an excellent showing, seeing out the month ~11% into the green, in what amounted to its best start to a year since 2001. That signals the appetite for risk is on again and that will be good news for Cathie Wood, the ARK Investment CEO, whose investing style heavily favors disruptors - equities that are naturally positioned at the risky end of the sca